Spectral Domain Optical Coherence Tomography Analysis for Glaucoma

Comparison of Ganglion Cell and Retinal Nerve Fiber Layer Thickness in Primary Open Angle Glaucoma and Normal Tension Glaucoma With Spectral Domain OCT

NCT01612416•Inonu University

View on ClinicalTrials.gov

Summary

The aim of this study is to examine whether there is a difference in macular ganglion cell complex thickness and retinal nerve fiber layer thickness in early-stage Primary open angle glaucoma and normal tension glaucoma with spectral domain OCT.

Detailed Description

Glaucoma is a progressive optic neuropathy characterized by gradual degeneration of neuronal tissue in which retinal ganglion cells (RGCs) are injured, leading to the loss of the visual field.Recent studies have separately demonstrated a reduction in the macular retinal thickness and in the retinal nerve fibers in both POAG and NTG.It has been demonstrated that in early stage NTG macular GCC thickness showed a strong correlation with thickness of the RNFL. However there have yet to be any reports regarding the comparison of macular thickness, ganglion cell complex and retinal nerve fiber layer between POAG and NTG with RS-3000 RetinaScan at early stage.

Eligibility

Age

28 - 72 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•IOP higher than 21 mmHg before treatment on three different visits,
•Best corrected VA of 20/25 or better with a spherical equivalent within ±5 D and a cylinder correction within +3 D;
•An open angle confirmed by gonioscopy.
•Glaucomatous optic disc damage defined as by the presence of glaucomatous optic neuropathy like rim thinning (diffuse or local), cupping, notching, and a cup/disc ratio \>0.2 with asymmetry.
•NTG group were included if;
•They had the same optic disc and visual field criteria as for the POAG patients with the exception that their IOP was as ≤21 mmHg on three separate visits without any glaucomatous treatment.
•The control group
•Who had no ocular disease
•Who had not undergone ocular surgery or laser procedures.
•With a normal anterior segment, open angles, and normal posterior segment findings also normal optic nerve head appearance in their ophthalmic examination.
+1 more criteria

Exclusion Criteria

•Subjects with any retinal disease, diabetes mellitus, or neurological disease or who had undergone ocular surgery and laser procedures.
•Subjects with pseudoexfoliation glaucoma and pigmentary glaucoma were excluded.

Locations (1)

Inonu University School of Medicine

Malatya, Turkey (Türkiye)

Key Dates

Start Date

November 1, 2010

Primary Completion Date

June 1, 2011

Completion Date

June 1, 2011

Last Updated

June 5, 2012

Enrollment

169

ACTUAL participants

Conditions

GLAUCOMA 1, OPEN ANGLE, D (Disorder)

Interventions

RS-3000 OCT measurements

DEVICE

Comparing XEN®-63 Gel Stent and PRESERFLO® MicroShunt

NCT07359547

GLAUCOMA 1, OPEN ANGLE, D (Disorder)

View study

RECRUITING

24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring

NCT06689696

GlaucomaGLAUCOMA 1, OPEN ANGLE, D (Disorder)+9 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 5, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions